| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5780676 | VALEANT LUXEMBOURG | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(8 years ago) | |
| US5962731 | VALEANT LUXEMBOURG | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(7 years ago) | |
Targretin is owned by Valeant Luxembourg.
Targretin contains Bexarotene.
Targretin has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Targretin are:
- US5780676
- US5962731
Targretin was authorised for market use on 29 December, 1999.
Targretin is available in capsule;oral dosage forms.
Targretin can be used as treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
The generics of Targretin are possible to be released after 29 July, 2018.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-164) | Jul 29, 2018 |
Drugs and Companies using BEXAROTENE ingredient
Market Authorisation Date: 29 December, 1999
Treatment: Treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy
Dosage: CAPSULE;ORAL
TARGRETIN family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5780676 | BAUSCH | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(8 years ago) | |
| US5962731 | BAUSCH | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(7 years ago) | |
Targretin is owned by Bausch.
Targretin contains Bexarotene.
Targretin has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Targretin are:
- US5780676
- US5962731
Targretin was authorised for market use on 28 June, 2000.
Targretin is available in gel;topical dosage forms.
Targretin can be used as topical treatment of cutaneous lesions in patients with cutaneous t-cell lymphoma (stage ia and ib) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
The generics of Targretin are possible to be released after 05 October, 2016.
Drugs and Companies using BEXAROTENE ingredient
Market Authorisation Date: 28 June, 2000
Treatment: Topical treatment of cutaneous lesions in patients with cutaneous t-cell lymphoma (stage ia and ib) who have refractory or persistent disease after other therapies or who have not tolerated other ther...
Dosage: GEL;TOPICAL
TARGRETIN family patents